4CPS-184 Comparison of safety and adherence of new oral therapies for the treatment of relapsing-remitting multiple sclerosis

BACKGROUND: Teriflunomide and dimethylfumarate are two new oral therapies for relapsing-remitting multiple sclerosis (RRMS). Due to the increase in patients with these treatments, face-to-face interviews were carried out with these patients in the outpatient area in order to obtain more information....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Torròn, A Martinez, María, MC Rosado, Martínez, A Arias, Fernandez, C Carriles, Romeo, A Llorente, Blanc, R Menarguez, López, E Lázaro, Ferreras, A Rodriguez, López, A Pieras, Tamames, B Zárate, Lozano-Blazquez, A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 4: Clinical pharmacy services
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535438/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.274
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller